Maxcyte Share Discussion Threads

[junior21] 07/5/2024 23:21

hxxps://www.fiercepharma.com/pharma/vertex-edges-out-bluebird-sickle-cell-gene-therapy-launch-cystic-fibrosis-franchise

Just found this. Vertex currently started on 5 patients. Will be interesting to see what contribution if any we get in the next two quarters

[junior21] 07/5/2024 23:02

Thanks Adam. Just seen that bluebird bio have had their first patient for the sickle cell therapy. Vertex declined to comment on whether they've started yet. Interesting to read the bluebird one costs $3.1m

[adamb1978] 07/5/2024 22:48

I think so. Have a look on their website

[junior21] 07/5/2024 22:36

Sensible approach to take.

Can the call be listened back to?

[adamb1978] 07/5/2024 21:52

Just listened to the Q1 conf call:

- they're clearly sandbagging the guidance, possibly understandably given 2023. Perhaps might not transformational (excl Vertex) but I'd have thought that 10%-15% core revenue growth is possibly a better bet than 0%-5%
- confidence coming back into the customer base, with a number of them having raised capital in Q1
- Forecasts exclude anything from the Vertex therapy as too tough to forecast.

Welcome relief to have Q1 looking better than the awful 2023

[mysteronz] 07/3/2024 13:47

It depends on your time horizon. They have set a non racey guidance - one hopes they atleast meet it.

Lets not forget they have had FDA approval, the first of its kind. It de-risks the whole investment thesis here. That is worth more to me than a +10% core revenue bump. This is likely to bob up and down a bit but something will likely go pop and i wouldnt want to be out of the stock then.

[sebass] 07/3/2024 12:05

I agree but they need something to be upbeat about. Guiding 3-5 SPL a year is not good enough. There is a lot of value in Biotech Maxcyte need to convince investors why they should park their cash with them.

[mysteronz] 07/3/2024 11:34

If you listen to the TD Cowan discussion thats what they have done, recognised they reduced expectations twice this year, dont want a repeat of it going forward.

One would assume then this is the base case and its surprise to the upside.

[davep4] 05/3/2024 21:54

Thinking about it, the RNS appears to be deliberately underwhelming.

[sebass] 05/3/2024 16:13

Maxcyte need to put themselves up for sale or be more agressive strategically. I haven't heard one word on their vlx platform at the presentation today. it's frustating to watch the slow progress any approvals in 2025? 2026-2027 was mentioned for the potential of 7 approvals 92

[junior21] 05/3/2024 13:58

davep4 1469 - I've seen similar numbers i.e. 3% of $2.2m per treatment

2024 guidance does seem very underwhelming. I'm hoping they're putting themselves in the under promise over deliver camp.

[davep4] 05/3/2024 11:59

Adam as you point out - SLP milestone payments of $3 is definitely underwhelming. Fingers crossed SPL Program-related revenue from CASGEVY saves the day? (I believe Vertex will be reporting the number of CASGEVY treatments on a quarterly basis).

[adamb1978] 05/3/2024 08:59

Not sure Dave. THe core revenue growth figure is underwhelming - new licenses are meant to tranlsate into incremental revenues...wonder whether:

- any licensees have terminated?
- any have asked for restructured/written off payments due to funding problems?
- MXCT have changed commercial structures?

[davep4] 05/3/2024 00:10

Any guesses what the SPL Program-related revenue from CASGEVY will be? (I believe it equates to around £6m per 100 treatments)

[davep4] 05/3/2024 00:07

2023 Preliminary Results
Total revenue for the fiscal year of 2023 is expected to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022.

Core revenue is expected to be between $29.6 million and $29.8 million, compared to $39.6 million for fiscal year 2022.
SPL Program-related revenue is expected to be approximately $11.4 million, compared to $4.6 million for fiscal year 2022.

Total cash, cash equivalents, and investments as of December 31, 2023 is expected to be approximately $210 million.

2024 Guidance
Management is providing initial 2024 revenue guidance for core business revenue and SPL program-related revenue:

Core revenue is expected to be flat to 5% growth compared to 2023.
SPL Program-related revenue is expected to be approximately $3 million for the year.

Our outlook does not include SPL Program-related revenue from the sale of Vertex/CRISPR’s CASGEVY™.
Management expects to end 2024 with $175 million in total cash, cash equivalents and investments.

[davep4] 05/3/2024 00:05

From Vertex Earnings Call Feb 05, 2024

“To help track our progress, our expectation is to provide quarterly updates on the number of activated ATCs, as well as the number of patients in the cell collection phase. ATCs have begun assessing their patients for the ability to be treated with CASGEVY, and we expect that the first commercial patients will start the journey in the coming weeks.”

[adamb1978] 30/1/2024 18:34

Certainly could be. COuld understand people holding back signing a long-term license agreement til it was proven.

Hopefully its not the new guy at the top accepting less attractive commercial terms

[mysteronz] 30/1/2024 16:38

These SPL signings are really starting to grow now.

Maybe a sign of increased confidence in bio investment or the MXCT platform, either way future money in the bank/sign on fee :)

[adamb1978] 08/1/2024 21:54

Thanks. Nice beat resulting from hte Vertex milestone payment. Hopefully they order piles more of the consumables for the next stage of that therapy and that with one test case through the FDA, it makes other customers more risk tolerant about submitting approval requests of their own

[davep4] 08/1/2024 21:23

Preliminary Unaudited Fourth Quarter and Full Year 2023 Results

Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.

Core revenue is expected to be between $7.0 million and $7.2 million, compared to $10.6 million in the fourth quarter of 2022.
Strategic Platform License (SPL) Program-related revenue is expected to be approximately $8.5 million, compared to $1.9 million in the fourth quarter of 2022.
Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.

Core revenue is expected to be between $29.6 million and $29.8 million, compared to $39.6 million for fiscal year 2022.
SPL Program-related revenue is expected to be approximately $11.4 million, compared to $4.6 million for fiscal year 2022.
Total cash, cash equivalents, and investments as of December 31, 2023 is expected to be approximately $210 million.

[davep4] 12/12/2023 13:20

Maybe the current share price performance resulted in DD being pushed into retirement? Whatever agreement has been reached it appears on the surface to be amicable.

Nevertheless, I am pleased that I will not have read about his continuous Exercise of Options and subsequent sale, (which in my opinion damaged the SP), furthermore, such Exercise of Options indicates to me that he knew he was going.

[adamb1978] 12/12/2023 06:25

Well I guess it was perhaps a $5m fee or so on FDA approval. THey had suggested before that they might be able to make the $6m without this, but the wording around it made it sound like a stretch. Now its "at least" $10m

DD retirement is a surprise, or at least the very near-term date. Wonder whether he's ill or something.

[junior21] 12/12/2023 05:36

Last SPL guidance was $6m so modest but welcome increase

[davep4] 11/12/2023 23:55

Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte

Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024

MaxCyte is reiterating 2023 expected core business revenue of $28-30 million, and the Company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million